Please assess the completion status of the following clinical trial:

Trial Title: Selection of Farnesoid X Receptor (FXR) Ligands on the Reactivation of Latent HIV Proviruses

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Criteria relating to the population studied: patients aged 18 to 65 years old, men or women, regardless of ethnic origin.~* Nosological criteria: HIV-1 infection, documented by a complete western blot and/or a detectable viral load at the time of diagnosis, regardless of the viral subtype.~* Pathology severity and progression criteria: patients with a CD4+ count greater than 500 elements/mm3 at the last follow-up visit prior to inclusion in the study. Undetectable viral load for at least six months on stable treatment.~* Criteria relating to treatments/strategies/procedures: Current cART treatment mandatory, regardless of the combination of anti-retrovirals, effective with undetectable viral load. The number of processing lines is not limited.~* Criteria relating to regulation: Absence of opposition~Exclusion Criteria:~* Criteria relating to the population studied: pregnant or breastfeeding women~* Criteria relating to contraindications to the protocol explorations:~Acute or chronic anaemias Acute infections, fever Coagulation disorders, patients taking anticoagulants~- Criteria relating to regulation: Subjects placed under judicial safeguard, guardianship or curatorship Subjects participating in another research with an ongoing exclusion period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Adult patients infected by HIV, controlled under treatment. (Type: EXPERIMENTAL): Blood sample collection from HIV controlled patients during their scheduled consultation, after obtaining their non-opposition by an investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).